[Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].

Autor: Roppelt AA; City Clinical Hospital №52.; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology., Lebedkina MS; City Clinical Hospital №52., Chernov AA; City Clinical Hospital №52.; Russian Medical Academy of Continuous Professional Education., Kruglova TS; City Clinical Hospital №52., Mukhina OA; City Clinical Hospital №52., Yukhnovskaya YD; Sechenov First Moscow State Medical University (Sechenov University)., Samedova FA; Sechenov First Moscow State Medical University (Sechenov University)., Mаrkina UA; City Clinical Hospital №52., Andrenova GV; City Clinical Hospital №52., Karaulov AV; Sechenov First Moscow State Medical University (Sechenov University)., Lysenko MA; City Clinical Hospital №52.; Pirogov Russian National Research Medical University., Fomina DS; City Clinical Hospital №52.; Sechenov First Moscow State Medical University (Sechenov University).

Publikováno v: Terapevticheskii arkhiv [Ter Arkh] 2023 Feb 24; Vol. 95 (1), pp. 78-84. Date of Electronic Publication: 2023 Feb 24.